New Treatment Option for Mesothelioma
A new drug in the treatment arsenal for mesothelioma is always welcomed. Recently, an Orphan Drug Designation was granted by the US Food and Drug Administration for tremelimumab, an anti-CTLA-4 monoclonal antibody. Robert Iannone, Senior Vice President and Head of Immuno-oncology, Global Medicines Development at AstraZeneca announced, “There is a significant need for new treatment …